Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, through its innovation arm Oxford University Innovation (OUI), has entered into an option agreement for a universal influenza vaccine with US-based startup Blue Water Vaccines (BWV), which is raising $15m to support development of the flu shot.

3D rendering of microscopic virus in front of abstract background © Shutterstock

Developed by scientists at the University’s Department of Zoology the vaccine protects against all influenza strains by targeting parts of the virus that induce a protective immune response but are also limited in variability. The technology has the potential of providing life-long immunity against flu.

Influenza is a major respiratory pathogen. It is estimated that there are over almost 500,000 deaths a year caused by influenza, with somewhere between three to five million severe cases of illness annually. The virus is estimated to cost $87.1bn in absenteeism in the US alone. Current influenza vaccines target highly variable epitopes of the virus which evolve and change annually, meaning flu vaccines need to be updated and redistributed every season while only typically providing protection to 50% of the individuals who receive it. Conversely, the universal flu vaccine developed at Oxford University targets epitopes that are both naturally immunogenic and limited in variability, allowing for a vaccine that protects against all influenza strains and avoids the need to be regularly updated.

Read more (University of Oxford website)

Similar stories

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.